Fusen Pharmaceutical Co Ltd

Fusen Pharmaceutical Co Ltd has a liquidity risk profile marked by a current ratio of 0.56, indicating that its current assets are insufficient to cover its current liabilities. The company's cash and equivalents of CNY 83.84 million are significantly lower than its total liabilities of CNY 904.18 million, and its long-term debt of CNY 301.23 million further strains its liquidity position. The debt-to-equity ratio of 0.84 suggests a moderate reliance on debt financing, but the negative net income of CNY -11.78 million and operating income of CNY -1.72 million indicate financial stress. Profitability metrics for Fusen Pharmaceutical Co Ltd are weak compared to industry norms. The company's return on equity of -3.28% and return on assets of -0.93% are both negative, signaling poor capital efficiency and asset utilization. These figures fall well below the typical performance of pharmaceutical firms, which usually maintain positive returns on equity and assets. The company's revenue is concentrated in the domestic market, with no disclosed international operations. Its main products, Shuanghuanglian Oral Solutions and Injections, are central to its revenue generation, but the lack of diversification in product lines or geographic reach increases its exposure to local market risks. Fusen Pharmaceutical Co Ltd's growth trajectory is uncertain, with no clear indication of revenue expansion in the near term. The company reported a revenue of CNY 273.37 million in the latest period, but the absence of a positive outlook for the current or next fiscal year suggests ongoing challenges in driving top-line growth. The risk assessment for Fusen Pharmaceutical Co Ltd highlights liquidity concerns, with a medium risk rating. The company's negative net cash position, after subtracting total debt, indicates a potential inability to meet short-term obligations without external financing. The dilution risk is currently low, but the company's financial performance and capital structure suggest a need for close monitoring of potential equity issuance. Recent events and filings for Fusen Pharmaceutical Co Ltd have not been disclosed in the available data, limiting the ability to assess any material developments that may impact its operations or financial position. The absence of recent transcripts or filings suggests a lack of transparency or public communication regarding the company's strategic direction or financial health.